Anaplastic oligodendroglioma (WHO grade III) revealed sparse tumor cell-associated GAL1-R-immunoreactivity in 17% of samples (<1% of tumor cells; Figure 6E). This evidence concerns the gene GALR1 and oligodendroglioma.